Emory University

Differences in Acute Graft-Versus-Host Disease (GVHD) Severity and Its Outcomes Between Black and White Patients (2024) Rios CA, Qayed M, Etra AM, Reshef R, Newcomb R, Yuhasz N, Hexner EO, et al. Journal article Clinical practice guidelines for the care of girls and women with Turner syndrome Proceedings from the 2023 Aarhus International Turner Syndrome Meeting (2024) Gravholt CH, Andersen NH, Christin-Maitre S, Davis SM, Duijnhouwer A, Gawlik A, Maciel-Guerra AT, et al. Journal article Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD (2024) Akahoshi Y, Spyrou N, Weber D, Aguayo-Hiraldo P, Ayuk F, Chanswangphuwana C, Choe HK, et al. Journal article Endovascular therapy of isolated posterior cerebral artery occlusion stroke with and without general anesthesia (2024) Berberich A, Herweh C, Qureshi MM, Strambo D, Michel P, Räty S, Abdalkader M, et al. Journal article Integrative multi-omics analyses to identify the genetic and functional mechanisms underlying ovarian cancer risk regions (2024) Dareng EO, Coetzee SG, Tyrer JP, Peng PC, Rosenow W, Chen S, Davis BD, et al. Journal article Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis. (2024) Akahoshi Y, Spyrou N, Hoepting M, Aguayo-Hiraldo P, Ayuk F, Chanswangphuwana C, Choe HK, et al. Journal article Scoring PD-L1 Expression in Urothelial Carcinoma: An International Multi-Institutional Study on Comparison of Manual and Artificial Intelligence Measurement Model (AIM-PD-L1) Pathology Assessments (2024) Rüschoff J, Kumar G, Badve S, Jasani B, Krause E, Rioux-Leclercq N, Rojo F, et al. Journal article De novo variants predicting haploinsufficiency for DIP2C are associated with expressive speech delay (2024) Ha T, Morgan A, Bartos MN, Beatty K, Cogné B, Braun D, Gerber CB, et al. Journal article Update on olfactory neuroblastoma (2024) Lopez F, Agaimy A, Franchi A, Suárez C, Vander Poorten V, Mäkitie AA, Homma A, et al. Journal article, Review article Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease (2023) Al Malki MM, London K, Baez J, Akahoshi Y, Hogan WJ, Etra A, Choe H, et al. Journal article